首頁 > 市場調查報告書 > 醫療設備

心血管設備呼吸器

市場調查報告書

商品編碼

1422741

全球心肺運動測試（CPET）市場預測（截至2030年）

Cardiopulmonary Exercise Testing Market Research Report Forecast till 2030

出版日期: 2024年01月07日 | 出版商:

Market Research Future | 英文 101 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

心肺運動測試 (CPET) 市場規模預計在預測期內將以 7.25% 的複合年增長率穩定成長。

全球心血管感染和肺動脈高壓的增加正在推動該市場的成長。心血管疾病的增加趨勢是由多種因素造成的，包括人口老化、吸菸、空氣污染和飲食習慣。

本報告調查了全球心肺運動測試(CPET) 市場，並提供了市場定義和概述、對市場增長的各種影響因素的分析、市場規模趨勢和預測，以及按各個細分市場和地區進行的細分。市場細分、競爭環境以及主要公司的概況進行了總結。

The developing pervasiveness of cardiovascular infections like cardiovascular breakdown, and aspiratory hypertension among others across the globe is driving the development of the cardiopulmonary exercise testing market. Cardiopulmonary exercise testing gives important symptomatic data and assists in deciding with practicing limit and utilitarian limits in patients with these circumstances. As per the article distributed by Public Community for Biotechnology Data in June 2022, the test can give both cardiovascular and pneumonic sickness processes, while helping with the advancement of individualized treatment and recovery programs. Also, the rising commonness of cardiovascular sicknesses can be credited to different variables, including maturing populaces, stationary ways of life, smoking, air contamination, and unfortunate eating regimens. As these illnesses progress, they lead to practical impediments, diminished exercise resilience, and hindered cardiopulmonary wellness. In this specific circumstance.

The geriatric populace is more inclined to ongoing infections and grown-ups matured 65 and more seasoned are more probable than more youthful individuals to experience the ill effects of cardiovascular sickness. Maturing can likewise cause a gamble of creating cardiovascular infection. Hence, the rising populace of this part of individuals can likewise build the interest for cardiopulmonary exercise testing to survey a person's cardiovascular and respiratory capabilities.

Accordingly, the developing predominance of cardiovascular illnesses and other constant sicknesses and expanding utilizations of radioisotopes in the medical services industry are energizing market development.

Market Segmentation

The Cardiopulmonary Exercise Testing Market has been divided into two segments based on product type: software and CPET metabolic carts.

The Cardiopulmonary Exercise Testing Market has been divided into ambulatory centers, diagnostic centers, hospitals & clinics, and others based on the end user.

Regional Insights

North America is likely to lead the market owing to a largest market contribution of 37.77% in 2022.

Furthermore, the region's significant development is emphatically impacted by expanding rates of cardiovascular sicknesses (CVD), which increment the interest for cardiopulmonary exercise testing (CPET) programming and CPET metabolic trucks. The CPET metabolic trucks and programming are used in CVDs to offer an assessment of the respiratory, cardiovascular, and skeletal muscle frameworks' coordinated exercise reactions.

The Europe region shows critical development during the forecast time frame. This is because of the rising predominance of persistent sicknesses like cardiovascular illnesses, respiratory problems, and metabolic circumstances that is driving the interest for CPET in Europe. CPET gives important analytic and prognostic data for these circumstances, supporting customized treatment and the board methodologies.

The development of the market in Asia-Pacific is anticipated to rise quickly because of an attributable to high utilizations of CPET in the geriatric populace as maturing populaces are more inclined to CVDs. According to the Asia-Pacific Report on Populace Maturing 2022, there were around 670 million individuals matured 60 or more established in Asia-Pacific in 2022. Besides, the possibilities having CVDs expansion in diabetic patients, which expands the interest for CPET gadgets.

Major Players

Key Companies in the Cardiopulmonary Exercise Testing Market includes Schiller AG, COSMED srl, MGC Diagnostics Corporation, Oxigraf, Inc, Vyaire Medical, Inc, CORTEX Biophysik GmbH, Koninklijke Philips NV, Hill-Rom Holdings, Inc, MEDEV Medical Devices Corporation, Geratherm Medical AG, Schiller AG, COSMED srl, and Others.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.6.1 BOTTOM-UP APPROACH
- 3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW
4.2 DRIVERS
- 4.2.1 INCREASE IN THE PREVALENCE OF CARDIOVASCULAR DISEASES
- 4.2.2 RISING GERIATRIC POPULATION
4.3 RESTRAINTS
- 4.3.1 LACK OF SKILLED AND EXPERIENCED PROFESSIONALS
4.4 OPPORTUNITIES
- 4.4.1 GROWING NUMBER OF STRATEGIC INITIATIVES

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D & DESIGNING
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION & SALES
- 5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET
- 5.3.1 IMPACT ON SUPPLY CHAIN
- 5.3.2 IMPACT ON KEY PLAYERS
- 5.3.3 IMPACT ON DEMAND
5.4 QUANTITATIVE MARKET INSIGHTS
- 5.4.1 NUMBER OF CPET METABOLIC CARTS BY REGION, 2022
- 5.4.2 AVERAGE TESTS PERFORMED IN 2022, BY TYPE OF FACILITIES, BY REGION, 2022
5.5 QUALITATIVE CONSUMER ASSESSMENT
- 5.5.1 DEMAND FOR CPET SOFTWARE IN MAJOR REGIONS
- 5.5.2 AVERAGE TIME REQUIRED FOR INTERPRETING CPET TESTS, INCLUDING REPORTING.
- 5.5.3 % CHANCES OF ADOPTION OF TECHNOLOGICAL ADVANCEMENTS SUCH AS SEMI-AUTOMATIC INTERPRETATION PROGRAM
- 5.5.4 RANGE OF % PROFITS BY FACILITIES PERFORMING CPET TESTS
- 5.5.5 % INVESTMENTS IN CPET SOFTWARE

6 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT

6.1 OVERVIEW
6.2 CPET METABOLIC CARTS
6.3 SOFTWARE

7 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, BY END USER

7.1 OVERVIEW
7.2 HOSPITALS & CLINICS
7.3 DIAGNOSTIC CENTERS
7.4 AMBULATORY CENTERS
7.5 OTHERS

8 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, BY REGION

8.1 OVERVIEW
8.2 NORTH AMERICA
- 8.2.1 US
- 8.2.2 CANADA
8.3 EUROPE
- 8.3.1 GERMANY
- 8.3.2 FRANCE
- 8.3.3 UK
- 8.3.4 ITALY
- 8.3.5 SPAIN
- 8.3.6 REST OF EUROPE
8.4 ASIA-PACIFIC
- 8.4.1 CHINA
- 8.4.2 INDIA
- 8.4.3 JAPAN
- 8.4.4 AUSTRALIA
- 8.4.5 SOUTH KOREA
- 8.4.6 REST OF ASIA-PACIFIC
8.5 REST OF THE WORLD
- 8.5.1 MIDDLE EAST
- 8.5.2 AFRICA
- 8.5.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW
9.2 COMPETITIVE BENCHMARKING
9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET
9.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET
9.5 KEY DEVELOPMENT ANALYSIS
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 9.6.1 PRODUCT/COMPANY LAUNCH/PRODUCT APPROVAL
- 9.6.2 COLLABORATION/AGREEMENT
9.7 FINANCIAL MATRIX
- 9.7.1 SALES (USD MILLION), 2021
- 9.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2021

10 COMPANY PROFILES

10.1 SCHILLER AG
- 10.1.1 COMPANY OVERVIEW
- 10.1.2 FINANCIAL OVERVIEW
- 10.1.3 PRODUCTS OFFERED
- 10.1.4 KEY DEVELOPMENTS
- 10.1.5 SWOT ANALYSIS
- 10.1.6 KEY STRATEGIES
10.2 COSMED SRL
- 10.2.1 COMPANY OVERVIEW
- 10.2.2 FINANCIAL OVERVIEW
- 10.2.3 PRODUCTS OFFERED
- 10.2.4 KEY DEVELOPMENTS
- 10.2.5 SWOT ANALYSIS
- 10.2.6 KEY STRATEGIES
10.3 MGC DIAGNOSTICS CORPORATION
- 10.3.1 COMPANY OVERVIEWS
- 10.3.2 FINANCIAL OVERVIEW
- 10.3.3 PRODUCTS OFFERED
- 10.3.4 KEY DEVELOPMENTS
- 10.3.5 KEY STRATEGIES
10.4 OXIGRAF, INC
- 10.4.1 COMPANY OVERVIEW
- 10.4.2 FINANCIAL OVERVIEW
- 10.4.3 PRODUCTS OFFERED
- 10.4.4 KEY DEVELOPMENTS
- 10.4.5 KEY STRATEGIES
10.5 VYAIRE MEDICAL, INC
- 10.5.1 COMPANY OVERVIEW
- 10.5.2 FINANCIAL OVERVIEW
- 10.5.3 PRODUCTS OFFERED
- 10.5.4 KEY DEVELOPMENTS
- 10.5.5 KEY STRATEGIES
10.6 CORTEX BIOPHYSIK GMBH
- 10.6.1 COMPANY OVERVIEW
- 10.6.2 FINANCIAL OVERVIEW
- 10.6.3 PRODUCTS OFFERED
- 10.6.4 KEY DEVELOPMENTS
- 10.6.5 KEY STRATEGIES
10.7 KONINKLIJKE PHILIPS N.V.
- 10.7.1 COMPANY OVERVIEW
- 10.7.2 FINANCIAL OVERVIEW
- 10.7.3 PRODUCTS OFFERED
- 10.7.4 KEY DEVELOPMENTS
- 10.7.5 SWOT ANALYSIS
- 10.7.6 KEY STRATEGIES
10.8 HILL-ROM HOLDINGS, INC
- 10.8.1 COMPANY OVERVIEW
- 10.8.2 FINANCIAL OVERVIEW
- 10.8.3 PRODUCTS OFFERED
- 10.8.4 KEY DEVELOPMENTS
- 10.8.5 KEY STRATEGIES
10.9 MEDEV MEDICAL DEVICES CORPORATION
- 10.9.1 COMPANY OVERVIEW
- 10.9.2 FINANCIAL OVERVIEW
- 10.9.3 PRODUCTS OFFERED
- 10.9.4 KEY DEVELOPMENTS
- 10.9.5 SWOT ANALYSIS
- 10.9.6 KEY STRATEGIES
10.10 GERATHERM MEDICAL AG
- 10.10.1 COMPANY OVERVIEW
- 10.10.2 FINANCIAL OVERVIEW
- 10.10.3 PRODUCTS OFFERED
- 10.10.4 KEY DEVELOPMENTS
- 10.10.5 SWOT ANALYSIS
- 10.10.6 KEY STRATEGIES

11 APPENDIX

11.1 REFERENCES
11.2 RELATED REPORTS

簡介目錄圖表

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
TABLE 3 NUMBER OF CPET METABOLIC CARTS, BY REGION, 2022
TABLE 4 AVERAGE TESTS PERFORMED, BY REGION, 2022
TABLE 5 AVERAGE TIME REQUIRED FOR INTERPRETING CPET TESTS
TABLE 6 RANGE OF % PROFITS BY FACILITIES PERFORMING CPET TESTS
TABLE 7 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
TABLE 8 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, FOR CPET METABOLIC CARTS, BY REGION, 2019-2030 (USD MILLION)
TABLE 9 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, FOR SOFTWARE, BY REGION, 2019-2030 (USD MILLION)
TABLE 10 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, BY END USER, 2019-2030 (USD MILLION)
TABLE 11 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, FOR HOSPITALS & CLINICS, BY REGION, 2019-2030 (USD MILLION)
TABLE 12 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, FOR DIAGNOSTIC CENTERS, BY REGION, 2019-2030 (USD MILLION)
TABLE 13 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, FOR AMBULATORY CENTERS, BY REGION, 2019-2030 (USD MILLION)
TABLE 14 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, FOR OTHERS, BY REGION, 2019-2030 (USD MILLION)
TABLE 15 GLOBAL: CARDIOPULMONARY EXERCISE TESTING MARKET, BY REGION, 2019-2030 (USD MILLION)
TABLE 16 NORTH AMERICA: CARDIOPULMONARY EXERCISE TESTING MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
TABLE 17 NORTH AMERICA: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
TABLE 18 NORTH AMERICA: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019-2030 (USD MILLION)
TABLE 19 US: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
TABLE 20 US: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019-2030 (USD MILLION)
TABLE 21 CANADA: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
TABLE 22 CANADA: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019-2030 (USD MILLION)
TABLE 23 EUROPE: CARDIOPULMONARY EXERCISE TESTING MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
TABLE 24 EUROPE: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
TABLE 25 EUROPE: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019-2030 (USD MILLION)
TABLE 26 GERMANY: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
TABLE 27 GERMANY: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019-2030 (USD MILLION)
TABLE 28 FRANCE: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
TABLE 29 FRANCE: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019-2030 (USD MILLION)
TABLE 30 UK: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
TABLE 31 UK: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019-2030 (USD MILLION)
TABLE 32 ITALY: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
TABLE 33 ITALY: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019-2030 (USD MILLION)
TABLE 34 SPAIN: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
TABLE 35 SPAIN: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019-2030 (USD MILLION)
TABLE 36 REST OF EUROPE: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
TABLE 37 REST OF EUROPE: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019-2030 (USD MILLION)
TABLE 38 ASIA-PACIFIC: CARDIOPULMONARY EXERCISE TESTING MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
TABLE 39 ASIA-PACIFIC: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
TABLE 40 ASIA-PACIFIC: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019-2030 (USD MILLION)
TABLE 41 CHINA: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
TABLE 42 CHINA: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019-2030 (USD MILLION)
TABLE 43 INDIA: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
TABLE 44 INDIA: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019-2030 (USD MILLION)
TABLE 45 JAPAN: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
TABLE 46 JAPAN: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019-2030 (USD MILLION)
TABLE 47 AUSTRALIA: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
TABLE 48 AUSTRALIA: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019-2030 (USD MILLION)
TABLE 49 SOUTH KOREA: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
TABLE 50 SOUTH KOREA: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019-2030 (USD MILLION)
TABLE 51 REST OF ASIA-PACIFIC: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
TABLE 52 REST OF ASIA-PACIFIC: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019-2030 (USD MILLION)
TABLE 53 REST OT THE WORLD: CARDIOPULMONARY EXERCISE TESTING MARKET, BY REGION, 2019-2030 (USD MILLION)
TABLE 54 REST OT THE WORLD: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
TABLE 55 REST OT THE WORLD: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019-2030 (USD MILLION)
TABLE 56 MIDDLE EAST: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
TABLE 57 MIDDLE EAST: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019-2030 (USD MILLION)
TABLE 58 AFRICA: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
TABLE 59 AFRICA: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019-2030 (USD MILLION)
TABLE 60 LATIN AMERICA: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
TABLE 61 LATIN AMERICA: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019-2030 (USD MILLION)
TABLE 62 MAJOR PLAYERS IN THE GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET
TABLE 63 MOST ACTIVE PLAYER IN THE GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET
TABLE 64 PRODUCT/COMPANY LAUNCH/PRODUCT APPROVAL
TABLE 65 COLLABORATION/AGREEMENT
TABLE 66 SCHILLER AG: PRODUCTS OFFERED
TABLE 67 COSMED SRL: PRODUCTS OFFERED
TABLE 68 COSMED SRL: KEY DEVELOPMENTS
TABLE 69 MGC DIAGNOSTICS CORPORATION: PRODUCTS OFFERED
TABLE 70 MGC DIAGNOSTICS CORPORATION: KEY DEVELOPMENTS
TABLE 71 OXIGRAF, INC: PRODUCTS OFFERED
TABLE 72 VYAIRE MEDICAL, INC: PRODUCTS OFFERED
TABLE 73 CORTEX BIOPHYSICS GMBH: PRODUCTS OFFERED
TABLE 74 KONINKLIJKE PHILIPS NV: PRODUCTS OFFERED
TABLE 75 HILL-ROM HOLDINGS, INC: PRODUCTS OFFERED
TABLE 76 MEDEV MEDICAL DEVICES CORPORATION: PRODUCTS OFFERED
TABLE 77 GERATHERM MEDICAL AG: PRODUCTS OFFERED

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS
FIGURE 2 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET
FIGURE 5 DRIVER IMPACT ANALYSIS
FIGURE 6 RESTRAINT IMPACT ANALYSIS
FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET
FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET
FIGURE 9 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, PRODUCT SEGMENT ATTRACTIVENESS, 2019-2030 (USD MILLION)
FIGURE 10 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2022 & 2030 (USD MILLION)
FIGURE 11 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET SHARE (%), BY PRODUCT, 2022
FIGURE 12 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, END USER SEGMENT ATTRACTIVENESS, 2019-2030 (USD MILLION)
FIGURE 13 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, BY END USER, 2022 & 2030 (USD MILLION)
FIGURE 14 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET SHARE (%), BY END USER, 2022
FIGURE 15 GLOBAL: CARDIOPULMONARY EXERCISE TESTING MARKET, BY REGION, 2022 & 2030 (USD MILLION)
FIGURE 16 GLOBAL: CARDIOPULMONARY EXERCISE TESTING MARKET SHARE (%), BY REGION, 2022
FIGURE 17 NORTH AMERICA MARKET ANALYSIS: CARDIOPULMONARY EXERCISE TESTING MARKET, 2019-2030 (USD MILLION)
FIGURE 18 NORTH AMERICA: CARDIOPULMONARY EXERCISE TESTING MARKET, BY COUNTRY, 2022 & 2030 (USD MILLION)
FIGURE 19 NORTH AMERICA: CARDIOPULMONARY EXERCISE TESTING MARKET SHARE (%), BY COUNTRY, 2022
FIGURE 20 EUROPE MARKET ANALYSIS: CARDIOPULMONARY EXERCISE TESTING MARKET, 2019-2030 (USD MILLION)
FIGURE 21 EUROPE: CARDIOPULMONARY EXERCISE TESTING MARKET, BY COUNTRY, 2022 & 2030 (USD MILLION)
FIGURE 22 EUROPE: CARDIOPULMONARY EXERCISE TESTING MARKET SHARE (%), BY COUNTRY, 2022
FIGURE 23 NUMBER OF PEOPLE AGED 60 YEARS OR OVER IN ASIA-PACIFIC, BY SUB-REGIONS, 2022, 2030 AND 2050 (IN MILLIONS)
FIGURE 24 ASIA-PACIFIC MARKET ANALYSIS: CARDIOPULMONARY EXERCISE TESTING MARKET, 2019-2030 (USD MILLION)
FIGURE 25 ASIA-PACIFIC: CARDIOPULMONARY EXERCISE TESTING MARKET, BY COUNTRY, 2022 & 2030 (USD MILLION)
FIGURE 26 ASIA-PACIFIC: CARDIOPULMONARY EXERCISE TESTING MARKET SHARE (%), BY COUNTRY, 2022
FIGURE 27 REST OF THE WORLD MARKET ANALYSIS: CARDIOPULMONARY EXERCISE TESTING MARKET, 2019-2030 (USD MILLION)
FIGURE 28 REST OT THE WORLD: CARDIOPULMONARY EXERCISE TESTING MARKET, BY REGION, 2022 & 2030 (USD MILLION)
FIGURE 29 REST OT THE WORLD: CARDIOPULMONARY EXERCISE TESTING MARKET SHARE (%), BY REGION, 2022
FIGURE 30 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 31 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET
FIGURE 32 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET: COMPETITIVE LANDSCAPE
FIGURE 33 SALES 2021
FIGURE 34 RESEARCH & DEVELOPMENT EXPENDITURE, 2021
FIGURE 35 SCHILLER AG: SWOT ANALYSIS
FIGURE 36 COSMED SRL: SWOT ANALYSIS
FIGURE 37 KONINKLIJKE PHILIPS NV: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 38 KONINKLIJKE PHILIPS NV: SWOT ANALYSIS
FIGURE 39 MEDEV MEDICAL DEVICES CORPORATION: SWOT ANALYSIS
FIGURE 40 GERATHERM MEDICAL AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 41 GERATHERM MEDICAL AG: SWOT ANALYSIS